A randomized phase III study in previously untreated patients with biological high-risk CLL [chronic lymphocytic leukaemia]: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab

Trial Profile

A randomized phase III study in previously untreated patients with biological high-risk CLL [chronic lymphocytic leukaemia]: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Results (n=187) assessing effect of B-cell receptors stereotypy subsets on the primary outcome presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Jun 2013 Results of an analysis that investigated the effects of genetic mutations on outcomes (n=119) presented at the 18th Congress of the European Haematology Association.
    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top